Theratechnologies Inc T.TH

Question for the medical team

[SPCEO1]

And I really would like to see JFM1330 still be on that team!

What do you take away from the ever increasing number of cancers TH-1902 is targetting? Is this simply a result of ongoing pre-clinical testing on different tumors to determine how much sortilin they are over-expressing? Have we reached the end of the additions to the list or could there be many more? What are the chances if TH-1902 works on one cancer overexpressing sortilin that it would work on all others too? I have to think it is more complicated than that. JFM1330 has previously noted the hetergeneosity of cancer tumors in humans versus the xenografts the pre-clinical work is done on. Could the sortilin factor be strong enough to overcomme the differences in tumors?

[jeffm34]

One thing that bodes well for TH1902 is that Sortilin expression seems to be correlated with severity.  The more advanced and aggressive the cancer the more likely TH1902 will be effective. 

[qwerty22]

In my view you can think of basically two sources of info for that list. One comes from the scientific literature, research groups discovering sortilin in different cancer. The other comes from THTX's own work confirming those findings. A lot of the previous discoveries in cancer are collated into various databases online of the 1000's of different cancer markers/receptors/targets